EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?

Anurag S Rathore iD, Garima Thakur, Nikhil Kateja

Biotechnology and Bioengineering · 2023-02 · 120 (2) · 333-351

DOI: 10.1002/bit.28235 ↗

At a glance

Übersichtsarbeit in Biotechnology and Bioengineering, published online on 2022-09-28. Written by Anurag S Rathore and 2 co-authors. Institution: Department of Chemical Engineering, Indian Institute of Technology, New Delhi, India. Major MEDLINE topics: Technology, Pharmaceutical, Biological Products. Cited 42 times so far (Crossref); 139 references. Funded by: Council of Scientific and Industrial Research, India, Tata Consultancy Services, Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Continuous integrated bioprocessing has elicited considerable interest from the biopharma industry for the many purported benefits it promises. Today many major biopharma manufacturers around the world are engaged in the development of continuous process platforms for their products. In spite of great potential, the path toward continuous integrated bioprocessing remains unclear for the biologics industry due to legacy infrastructure, process integration challenges, vague regulatory guidelines, and a diverging focus toward novel therapies. In this article, we present a review and perspective on this topic. We explore the status of the implementation of continuous integrated bioprocessing among biopharmaceutical manufacturers. We also present some of the key hurdles that manufacturers are likely to face during this implementation. Finally, we hypothesize that the real impact of continuous manufacturing is likely to come when the cost of manufacturing is a substantial portion of the cost of product development, such as in the case of biosimilar manufacturing and emerging economies.

Subjects

MeSH terms (MEDLINE)

Technology, PharmaceuticalBiological ProductsDrug Industry

Author keywords

biopharmaceuticalscontinuous integrated bioprocessingmanufacturing platformsprocess integration

Substances

Biological Products

Authors and institutions

  • Department of Chemical Engineering, Indian Institute of Technology, New Delhi, India.

ORCID profiles: Anurag S Rathore

Funding

  • Council of Scientific and Industrial Research, India
  • Tata Consultancy Services
  • Department of Biotechnology, Ministry of Science and Technology, India

Cite

APA

Rathore, A. S., Thakur, G., & Kateja, N. (2023). Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?. Biotechnology and Bioengineering, 120(2), 333-351. https://doi.org/10.1002/bit.28235

Vancouver

Rathore AS, Thakur G, Kateja N. Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?. Biotechnology and Bioengineering. 2023;120(2):333-351. doi:10.1002/bit.28235

BibTeX
@article{Rathore2023,
  author = {Rathore, Anurag S and Thakur, Garima and Kateja, Nikhil},
  title = {Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?},
  journal = {Biotechnology and Bioengineering},
  year = {2023},
  volume = {120},
  number = {2},
  pages = {333--351},
  doi = {10.1002/bit.28235}
}
Start for free →